Literature DB >> 16596643

UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells.

Teresa Freire1, Nora Berois, Cecilia Sóñora, Mario Varangot, Enrique Barrios, Eduardo Osinaga.   

Abstract

The evaluation of disseminated epithelial tumor cells in patients with early stages of breast cancer has generated considerable interest because of its potential association with poor clinical outcome. Considering that O-glycosylation pathways are frequently altered in breast cancer, we performed this work to evaluate the potential usefulness of UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts) (a family of glycosyltransferases which catalyze the first key step of mucin-type O-glycosylation) to detect disseminated cells in bone marrow samples from patients with operable breast cancer. Using RT-PCR assays, we studied the gene expression of 9 enzymes (ppGalNAc-T1-T9). Among the ppGalNAc-Ts expressed by breast tumors (-T1, -T2, -T3, -T6 and -T7), the best specificity (negative results on all PBMN cell samples from healthy donors) was shown for ppGalNAc-T6. Thus, we selected this enzyme as a target gene for further evaluation. ppGalNAc-T6 mRNA was found in 22/25 (88%) breast cancer samples, in all 3 human breast cancer cell lines evaluated (MCF-7, ZR75-1 and T47D), in 1/30 (3%) PBMN cells and 0/19 bone marrow samples obtained from patients without cancer. Using this method, 22/61 (36%) patients with breast cancer, who underwent curative surgery, showed positive ppGalNAc-T6 mRNA in bone marrow aspirates obtained prior to surgery, including 11/34 patients with stage-I or -II, without histopathological lymph node involvement. In a preliminary follow-up evaluation, 19/61 patients experienced recurrence of the disease. ppGalNAc-T6 was positive in 11/19 (57.9%) of these patients. Interestingly, in the group of patients without lymph node involvement, disease recurrence was observed in 54.5% of patients who showed ppGalNAc-T6 mRNA-positive bone marrow aspirates and only in 4.3% of patients when ppGalNAc-T6 was negative (p = 0.014). These results indicate that ppGalNAc-T6 mRNA could be a specific marker applicable to the molecular diagnosis of breast cancer cells dissemination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596643     DOI: 10.1002/ijc.21959

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

Review 1.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  De novo expression of human polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) in colon adenocarcinoma inhibits the differentiation of colonic epithelium.

Authors:  Kirstine Lavrsen; Sally Dabelsteen; Sergey Y Vakhrushev; Asha M R Levann; Amalie Dahl Haue; August Dylander; Ulla Mandel; Lars Hansen; Morten Frödin; Eric P Bennett; Hans H Wandall
Journal:  J Biol Chem       Date:  2017-11-29       Impact factor: 5.157

Review 3.  Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family.

Authors:  Eric P Bennett; Ulla Mandel; Henrik Clausen; Thomas A Gerken; Timothy A Fritz; Lawrence A Tabak
Journal:  Glycobiology       Date:  2011-12-18       Impact factor: 4.313

Review 4.  The cellular microenvironment and cell adhesion: a role for O-glycosylation.

Authors:  Liping Zhang; Kelly G Ten Hagen
Journal:  Biochem Soc Trans       Date:  2011-01       Impact factor: 5.407

5.  Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin.

Authors:  Jae-Hyun Park; Toyomasa Katagiri; Suyoun Chung; Kyoko Kijima; Yusuke Nakamura
Journal:  Neoplasia       Date:  2011-04       Impact factor: 5.715

6.  Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma.

Authors:  Joana Gomes; Nuno T Marcos; Nora Berois; Eduardo Osinaga; Ana Magalhães; João Pinto-de-Sousa; Raquel Almeida; Fátima Gärtner; Celso A Reis
Journal:  J Histochem Cytochem       Date:  2008-10-14       Impact factor: 2.479

7.  N-Acetylglucosaminyltransferase III (GnT-III) but not N-Acetylgalactosaminyltransferase-6 and 8 are Differentially Expressed in Invasive and In Situ Ductal Carcinoma of the Breast.

Authors:  Antônio Felix da Silva Filho; Gabriela Souto Vieira-de-Mello; Petra Barros Dos Santos; Moacyr Jesus Barreto de Melo Rêgo; Alfredo Ribeiro-Silva; Eduardo Isidoro Carneiro Beltrão
Journal:  Pathol Oncol Res       Date:  2019-01-28       Impact factor: 3.201

Review 8.  Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma.

Authors:  Milada Stuchlová Horynová; Milan Raška; Henrik Clausen; Jan Novak
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

9.  Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylation.

Authors:  Earnest James Paul Daniel; Matilde Las Rivas; Erandi Lira-Navarrete; Ana García-García; Ramon Hurtado-Guerrero; Henrik Clausen; Thomas A Gerken
Journal:  Glycobiology       Date:  2020-10-21       Impact factor: 4.313

10.  Identification of triosephosphate isomerase as an anti-drug resistance agent in human gastric cancer cells using functional proteomic analysis.

Authors:  Xin Wang; Yuanyuan Lu; Jinghua Yang; Yongquan Shi; Mei Lan; Zhenxiong Liu; Huihong Zhai; Daiming Fan
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-29       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.